• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

鉴定膀胱癌中与预后和免疫治疗相关的 eRNA ID2-AS1。

Identification of prognostic and immunotherapy-related eRNA ID2-AS1 in bladder cancer.

机构信息

Department of Urology, Henan University People's Hospital, Henan Provincial People's Hospital, Zhengzhou, Henan, China.

出版信息

Medicine (Baltimore). 2022 Jul 1;101(26):e29759. doi: 10.1097/MD.0000000000029759.

DOI:10.1097/MD.0000000000029759
PMID:35776987
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9239636/
Abstract

AbstractEnhancer RNAs (eRNAs) can participate in enhancer regulation and target gene transcription, thus affecting the occurrence and development of tumors. In this study, we identified eRNAs closely related to bladder cancer (BLCA). Gene expression profiles and clinical information from The Cancer Genome Atlas (TCGA) database were used in this study. The Atlas of Noncoding RNAs in Cancer (TANRIC) co-expression data was also studied to evaluate correlations between the inferred levels of eRNA and its predicted target genes. Moreover, we evaluated differences in tumor microenvironment between high and low ID2-AS1 expression groups, and predicted the response of high- and low-expression groups to immune checkpoint inhibitor (ICI) treatment. Finally, we analyzed the prognostic value of ID2-AS1 in different tumors. ID2-AS1 and ID2 were identified as eRNAs and target genes related to the prognosis of BLCA. Low ID2-AS1 levels were associated with advanced age, low overall survival, high histological grade, and late BLCA staging. ID2-AS1 appeared to regulate epithelial mesenchymal transition, mitotic spindle assembly, and angiogenesis, thereby affecting BLCA progression. The ID2-AS1 high-expression group had better ICI treatment response. In addition, ID2-AS1 also had prognostic value in other cancers. ID2-AS1 helps predict prognostic and immunotherapeutic effects in BLCA.

摘要

摘要

增强子 RNA（eRNAs）可以参与增强子调控和靶基因转录，从而影响肿瘤的发生和发展。本研究旨在鉴定与膀胱癌（BLCA）密切相关的 eRNA。本研究使用了来自癌症基因组图谱（TCGA）数据库的基因表达谱和临床信息，并研究了癌症非编码 RNA 图谱（TANRIC）的共表达数据，以评估推断的 eRNA 与其预测靶基因之间的相关性。此外，我们评估了高低 ID2-AS1 表达组之间肿瘤微环境的差异，并预测了高表达组和低表达组对免疫检查点抑制剂（ICI）治疗的反应。最后，我们分析了 ID2-AS1 在不同肿瘤中的预后价值。ID2-AS1 和 ID2 被鉴定为与 BLCA 预后相关的 eRNA 和靶基因。低水平的 ID2-AS1 与年龄较大、总生存期较短、组织学分级较高和 BLCA 分期较晚有关。ID2-AS1 似乎调节上皮间质转化、有丝分裂纺锤体组装和血管生成，从而影响 BLCA 的进展。ID2-AS1 高表达组对 ICI 治疗的反应更好。此外，ID2-AS1 在其他癌症中也具有预后价值。ID2-AS1 有助于预测 BLCA 的预后和免疫治疗效果。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/595f/9239636/38a7f8cc5af1/medi-101-e29759-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/595f/9239636/802b3ca57222/medi-101-e29759-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/595f/9239636/a821abc61d48/medi-101-e29759-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/595f/9239636/574ff996dd67/medi-101-e29759-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/595f/9239636/0b4b75301e04/medi-101-e29759-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/595f/9239636/b238c1ec8291/medi-101-e29759-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/595f/9239636/0f7e44ab626d/medi-101-e29759-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/595f/9239636/38a7f8cc5af1/medi-101-e29759-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/595f/9239636/802b3ca57222/medi-101-e29759-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/595f/9239636/a821abc61d48/medi-101-e29759-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/595f/9239636/574ff996dd67/medi-101-e29759-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/595f/9239636/0b4b75301e04/medi-101-e29759-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/595f/9239636/b238c1ec8291/medi-101-e29759-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/595f/9239636/0f7e44ab626d/medi-101-e29759-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/595f/9239636/38a7f8cc5af1/medi-101-e29759-g007.jpg

相似文献

1
Identification of prognostic and immunotherapy-related eRNA ID2-AS1 in bladder cancer.鉴定膀胱癌中与预后和免疫治疗相关的 eRNA ID2-AS1。
Medicine (Baltimore). 2022 Jul 1;101(26):e29759. doi: 10.1097/MD.0000000000029759.
2
Identification and validation of telomerase related lncRNAs signature to predict prognosis and tumor immunotherapy response in bladder cancer.鉴定和验证端粒酶相关 lncRNAs 标志物，以预测膀胱癌的预后和肿瘤免疫治疗反应。
Sci Rep. 2023 Dec 9;13(1):21816. doi: 10.1038/s41598-023-49167-1.
3
Prognostic values of the immune microenvironment-related non-coding RNA IGF2BP2-AS1 in bladder cancer.膀胱癌中免疫微环境相关非编码 RNA IGF2BP2-AS1 的预后价值。
Cell Cycle. 2022 Dec;21(23):2533-2549. doi: 10.1080/15384101.2022.2103898. Epub 2022 Jul 27.
4
Identification of immune-related LncRNA for predicting prognosis and immunotherapeutic response in bladder cancer.鉴定免疫相关长链非编码 RNA 以预测膀胱癌的预后和免疫治疗反应。
Aging (Albany NY). 2020 Nov 18;12(22):23306-23325. doi: 10.18632/aging.104115.
5
Characterization of the immune related lncRNAs in bladder cancer to aid immunotherapy.膀胱癌免疫相关长链非编码 RNA 的特征分析辅助免疫治疗。
Front Immunol. 2022 Aug 26;13:941189. doi: 10.3389/fimmu.2022.941189. eCollection 2022.
6
The oncogenic role of TFAP2A in bladder urothelial carcinoma via a novel long noncoding RNA TPRG1-AS1/DNMT3A/CRTAC1 axis.TFAP2A通过一种新型长链非编码RNA TPRG1-AS1/DNMT3A/CRTAC1轴在膀胱尿路上皮癌中的致癌作用。
Cell Signal. 2023 Feb;102:110527. doi: 10.1016/j.cellsig.2022.110527. Epub 2022 Nov 21.
7
LncRNA TMPO-AS1 promotes proliferation and migration in bladder cancer.长链非编码 RNA TMPO-AS1 促进膀胱癌的增殖和迁移。
Eur Rev Med Pharmacol Sci. 2020 Sep;24(17):8740-8746. doi: 10.26355/eurrev_202009_22812.
8
LncRNA ID2-AS1 suppresses tumor metastasis by activating the HDAC8/ID2 pathway in hepatocellular carcinoma.长链非编码 RNA ID2-AS1 通过激活肝癌中的 HDAC8/ID2 通路抑制肿瘤转移。
Cancer Lett. 2020 Jan 28;469:399-409. doi: 10.1016/j.canlet.2019.11.007. Epub 2019 Nov 13.
9
Deciphering the immunological and prognostic features of bladder cancer through platinum-resistance-related genes analysis and identifying potential therapeutic target P4HB.通过铂耐药相关基因分析解析膀胱癌的免疫和预后特征，并鉴定潜在的治疗靶点 P4HB。
Front Immunol. 2023 Sep 18;14:1253586. doi: 10.3389/fimmu.2023.1253586. eCollection 2023.
10
Identification of cuproptosis-related long non-coding RNA and construction of a novel prognostic signature for bladder cancer: An observational study.铜死亡相关长链非编码RNA的鉴定及膀胱癌新预后特征的构建：一项观察性研究
Medicine (Baltimore). 2024 May 3;103(18):e38005. doi: 10.1097/MD.0000000000038005.

引用本文的文献

1
Enhancer RNA in cancer: identification, expression, resources, relationship with immunity, drugs, and prognosis.癌症中的增强子RNA：鉴定、表达、资源、与免疫的关系、药物及预后
Brief Funct Genomics. 2025 Jan 15;24. doi: 10.1093/bfgp/elaf007.
2
Novel enhancer mediates the readthrough loci and gene expressions associated with fabry disease.新型增强子介导与法布里病相关的通读位点和基因表达。
Front Genet. 2023 Dec 13;14:1229088. doi: 10.3389/fgene.2023.1229088. eCollection 2023.